Caribou Biosciences (CRBU) Institutional Ownership

During the previous two years, 109 institutional investors and hedge funds held shares of Caribou Biosciences. The most heavily invested institutionals were Avidity Partners Management LP ($36.44M), Vanguard Group Inc. ($21.13M), Deerfield Management Company L.P. Series C ($16.73M), Pictet Asset Management SA ($10.97M), PFM Health Sciences LP ($8.44M), Alkeon Capital Management LLC ($7.86M), and Kynam Capital Management LP ($5.11M).Learn more on CRBU's institutional investors.

77.51% of Caribou Biosciences stock is owned by institutional investors. Learn more on CRBU's institutional investor holdings.

Of the 94 institutional investors that purchased Caribou Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Avidity Partners Management LP ($3.60M), Deerfield Management Company L.P. Series C ($3.50M), JPMorgan Chase & Co. ($2.06M), Assenagon Asset Management S.A. ($1.89M), Renaissance Technologies LLC ($1.48M), Vanguard Group Inc. ($1.41M), and Jacobs Levy Equity Management Inc. ($1.21M).

Institutional investors have bought a total of 26,268,737 shares in the last 24 months. This purchase volume represents approximately $96.63M in transactions.

Of the 38 institutional investors that sold Caribou Biosciences stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Bank of America Corp DE ($2.80M), Assenagon Asset Management S.A. ($2.71M), Point72 Asset Management L.P. ($2.45M), Candriam S.C.A. ($520K), Pictet Asset Management SA ($487.70K), Jane Street Group LLC ($327.66K), and Dimensional Fund Advisors LP ($321.87K).

Institutional investors have sold a total of 11,713,908 shares in the last 24 months. This volume of shares sold represents approximately $34.49M in transactions.